Regnum CorpOOTC RGMP Stock Report

Regnum Corp. engages in developing and commercializing therapeutics that treat rare and infectious diseases. The company is headquartered in New York City, New York. The company went IPO on 2019-03-15. The firm is focused on late-stage commercial and clinical development programs. The firm is engaged in developing and commercializing therapeutics that treat rare and infectious diseases, specifically in populations that are neglected or face adherence challenges due to inconvenient dosing or delivery system, tolerability, or cost and accessibility of available therapeutic options. The firm's primary asset is the commercial rights to leronlimab (PRO 140) in all human immunodeficiency virus (HIV) indications within the United States. leronlimab is used as a platform drug for a variety of HIV indications. The target of leronlimab is the immunologic receptor C-C chemokine receptor type 5 (CCR5). Leronlimab prevents certain strains of HIV from using the CCR5 receptor as an entry gateway for healthy cells.